Has Ruth Rawlings, MD received payments from drug or device companies?

Yes. Drug and device makers reported $587 in general payments to Ruth Rawlings, MD across 33 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ruth Rawlings, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ruth Rawlings, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ruth Rawlings, MD

Gastroenterology · Alamogordo, NMNPI 1457790552

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $508 of the $587 with a category attached, or 86.7%. AbbVie accounts for 65.6% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $299, more than ten times the $28 reported in 2022. That places this record below the midpoint for gastroenterology clinicians in NM, where the typical reported total is $1,418.

$587in general payments, 2019–2025

Across 33 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$385
Johnson & Johnson$112
Pfizer$62
E.r. Squibb & Sons, L.L.C.$16
Conmed Corporation$12

What the payments were for

Food & beverage$50887%
Education$7813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	26	$385
Johnson & Johnson	3	$112
Pfizer	2	$62
E.r. Squibb & Sons, L.L.C.	1	$16
Conmed Corporation	1	$12

How this compares

$587 in reported general payments places this provider in the 30th percentile of 81 gastroenterology providers in New Mexico.

See all gastroenterology providers in New Mexico →

Medicare billing

Part B allowed, 2024

$148,472

Medicare patients

393

Services billed

2,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
StelaraUstekinumab	18	$486,477
CreonLipase/Protease/Amylase	51	$245,539
Humira(Cf) PenAdalimumab	13	$144,043
LinzessLinaclotide	27	$36,929
MotegrityPrucalopride Succinate	20	$29,028
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates	62	$3,642
Budesonide DrBudesonide	18	$2,151
Ursodiol	13	$1,950
Sucralfate	18	$1,487
Pantoprazole Sodium	110	$1,311
Balsalazide Disodium	11	$1,155
Colestipol Hcl	11	$941
Omeprazole	23	$476
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl	25	$373
Prednisone	12	$94

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonStelara	$112	$486,47718 claims
AbbVieCreon, Linzess	$385	$282,46878 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 81 gastroenterology providers in New Mexico.

Other gastroenterology in Alamogordo

Antoine JakicheAlbuquerque$108K
Fazia MirAlbuquerque$98K
Jean-Pierre ReinholdLas Cruces$79K
Christopher ChangAlbuquerque$51K
Stuart WeismanAlbuquerque$19K
Denis McCarthyAlbuquerque$17K
Kairasp NoshirwaniLas Cruces$10K
Andrei GasicAlbuquerque$9K
Daniel BujandaSanta Fe$8K
Amal ShineAlbuquerque$7K

See the full list for New Mexico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →